Hi KSD ..............I have not fully digested the report -- but found this, amongst other items (some way over my head) very interesting -page 99
Anteris is supported by Global Tier 1 Physicians, Scientists and Institutions ⚫ Anteris’ key investors are mostly physician led and based between New York and Australia ⚫ Due to its clinical results, Anteris is a potential acquisition target as it will disrupt current incumbents’ market share ⚫ Anteris also has the ability to commercialize alone and is therefore a credible threat to established players in a USD $10bn market by 2028
AVR Price at posting:
$23.85 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)